Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Your DNA may decide your diet success

NCT ID NCT06092372

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a person's genetic risk for obesity affects how much weight they lose on a diet. Researchers recruited 223 overweight adults with either very high or very low genetic risk scores for high body mass index (BMI). Half received diet coaching for 6 months, while the other half got no advice. The goal was to see if genetics can help predict who will benefit most from dietary changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

223 people

The number who actually took part.

Started

Oct 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 30-65 years old * body mass index (BMI) of 25-35 * participants with genetic data available * participants with a valid recontacting informed consent to their biobank Exclusion Criteria: * diagnosis of type I and II Diabetes Mellitus * history of bariatric surgery * diagnosis of schizophrenia and intellectual disability * diagnosis of dementia and Parkinson's * diagnosis of visual impairment * diagnosis of multiple sclerosis * pregnancy or breastfeeding during enrollment screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Body mass index (BMI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Finnish Clinical Biobank Tampere

    Tampere, Pirkanmaa, 33520, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.